Dividend and Share Repurchase - The company plans to distribute a cash dividend of RMB 8 per 10 shares, totaling RMB 464,809,076.80 (including tax), with an additional RMB 243,300,008.68 from share repurchases, making the total cash dividend RMB 708,109,085.48, representing 60.66% of the net profit attributable to shareholders[3] - The company's total share capital is 581,011,346 shares, excluding shares in the repurchase account[3] - The company's cash dividend and share repurchase combined amount to RMB 708,109,085.48, which is 60.66% of the net profit attributable to shareholders[3] - The company's board of directors has approved the 2022 profit distribution plan, which includes a cash dividend and share repurchase[3] - Cash dividend amount (including tax) is RMB 464,809,076.80, accounting for 39.81% of the net profit attributable to ordinary shareholders of the company[158] - Total dividend amount (including tax) is RMB 708,109,085.48, accounting for 60.66% of the net profit attributable to ordinary shareholders of the company[158] Subsidiaries and Business Operations - The company's subsidiaries include Autobio Technology, Autobio Instruments, and Autobio Shanghai, among others[8] - The company's subsidiaries are involved in various aspects of the biomedical and diagnostic industries, including molecular diagnostics and medical technology[8] - The company's subsidiaries are geographically diverse, with operations in cities such as Shanghai, Shenzhen, and Beijing[8] - The company's main business involves the production and sale of in vitro diagnostic reagents and instruments[10] - The company's main business is in the pharmaceutical manufacturing industry, specifically in the in-vitro diagnostic product manufacturing sector, focusing on the development, production, and integration of diagnostic reagents and instruments[40] - The company's product portfolio includes immunoassay reagents, microbial detection reagents, molecular diagnostic reagents, biochemical reagents, and related instruments[41] - The company has six core production lines, including immunoassay reagent production, microbial detection reagent production, biochemical reagent production, molecular diagnostic reagent production, POCT detection production, and instrument production[48] - The company's domestic sales are primarily conducted through a "distribution-based, direct sales-supplemented" model, with most sales achieved through distributors and a smaller portion directly to hospitals,体检 centers, and第三方检测机构[50] - The company's international sales have expanded to regions including the Middle East, Asia, Europe, the Americas, and Africa, with a focus on building local经销商 networks and providing professional training and technical support[51] Financial Performance - Revenue for 2022 reached 4,441,627,359.40 RMB, a 17.94% increase compared to 2021[18] - Net profit attributable to shareholders in 2022 was 1,167,437,129.39 RMB, up 19.90% year-over-year[18] - Operating cash flow for 2022 was 1,558,422,046.45 RMB, a 6.65% increase from 2021[18] - Total assets at the end of 2022 were 10,472,319,073.02 RMB, a 13.43% increase compared to the end of 2021[20] - Basic earnings per share for 2022 were 2.00 RMB, a 20.48% increase from 2021[21] - Weighted average return on equity (ROE) for 2022 was 15.57%, an increase of 1.34 percentage points from 2021[21] - Q4 2022 revenue was 1,160,146,358.97 RMB, with a net profit attributable to shareholders of 268,550,961.27 RMB[23] - Revenue for 2022 reached 4.442 billion yuan, a year-on-year increase of 17.94%[29] - Net profit attributable to shareholders of the listed company was 1.167 billion yuan, up 19.90% year-on-year[29] - Revenue for 2022 reached 4,441,627,359.40 RMB, a year-on-year increase of 17.94%[73][74] - Operating costs increased to 1,783,656,976.34 RMB, up 16.91% compared to the previous year[73][74] - R&D expenses grew by 18.20% to 568,476,026.60 RMB, reflecting increased investment in innovation[73][84] - Net cash flow from operating activities was 1,558,422,046.45 RMB, a 6.65% increase year-on-year[73] - Net cash flow from investing activities decreased by 91.59% to -978,664,819.27 RMB, mainly due to increased purchase of financial products[73] - Revenue from the in-vitro diagnostics sector grew by 18.44% to 4,365,865,645.71 RMB, with a gross margin of 60.71%[75] - Domestic revenue accounted for 4,235,856,555.90 RMB, a 17.56% increase, while overseas revenue surged by 56.76% to 130,009,089.81 RMB[77] - Sales through the distribution channel increased by 19.75% to 3,344,463,927.93 RMB, representing 64.06% of total sales[77] - Production of molecular diagnostic reagents surged by 174.71% to 898,340,000 units, with sales increasing by 266.39%[78] - Direct costs for the in-vitro diagnostics sector rose by 22.16% to 1,255,836,260.67 RMB, accounting for 73.21% of total costs[81] - Total R&D investment for the period was 571,694,787.59 RMB, accounting for 12.87% of total revenue, with 0.56% of R&D expenses capitalized[85] - Net cash flow from operating activities increased by 6.65% to 1,558,422,046.45 RMB, while net cash flow from investing activities decreased by 91.59% to -978,664,819.27 RMB due to increased purchase of financial products[88] - Monetary funds increased by 47.86% to 1,137,621,764.53 RMB, accounting for 10.86% of total assets, primarily due to cash reserves for operational needs[89] - Long-term equity investments increased by 523.68% to 10,755,004.86 RMB, mainly due to increased investment in a joint venture medical laboratory company[90] - Overseas assets amounted to 17,427,278.86 RMB, accounting for 0.17% of total assets[91] - Accounts payable increased by 32.72% to 296,297,340.11 RMB, primarily due to increased engineering payables[90] - Employee compensation payable increased by 42.48% to 192,537,690.02 RMB, mainly due to year-end performance bonus accruals[90] R&D and Innovation - R&D investment in 2022 was 571.6948 million yuan, accounting for 12.87% of revenue[29] - The company obtained 1,154 patents, including 51 international patents, and 651 product registration (filing) certificates[29] - Launched the Autolas X-1 Series automated testing equipment and the Autolumo A6000 series high-throughput chemiluminescence immunoassay analyzer[29] - Developed a respiratory pathogen nucleic acid detection solution capable of detecting 11 pathogens, including COVID-19[30] - Established a complete coagulation testing platform through strategic partnerships with domestic and international IVD companies[31] - The AutoiLab intelligent laboratory solution has been implemented in 29 medical institutions nationwide[32] - The company's reference laboratories in Zhengzhou and Beijing have been recognized by CNAS and JCTLM[31] - The company has a high-quality R&D team with 1,721 R&D personnel, accounting for 31.26% of the total workforce, and 90.94% of them hold bachelor's degrees or higher[52] - R&D investment in 2022 was RMB 571.69 million, accounting for 12.87% of the revenue, with consistent high investment in R&D over the past three years (11.63% in 2020, 12.90% in 2021)[52] - The company holds 1,154 patents, including 51 international patents, and has obtained 651 product registration (filing) certificates and 444 EU CE certifications[53] - Core raw materials such as antigens and antibodies are largely self-sufficient, ensuring supply stability and security[54] - The company has established multiple technology development platforms, including immunoassay, microbiology, molecular diagnostics, and biochemistry, supported by national and provincial research centers[55] - The company has obtained 651 product registration (filing) certificates and 444 EU CE certifications, covering a wide range of diagnostic fields[56] - The company's immunoassay products hold 242 registration (filing) certificates and 186 EU CE certifications, with a strong presence in both infectious and non-infectious disease diagnostics[58] - The microbiology product line includes 135 registered products and 71 EU CE certifications, with a significant market share in microbial culture monitoring[60] - The biochemistry product line comprises 189 registered/filed products, with 118 EU CE certifications, covering 12 major categories of clinical biochemistry testing[61] - The company developed a molecular diagnostic solution with 60+ projects and an automated RT-PCR system, obtaining 18 registrations and 46 CE certifications[62] - The company has accumulated 55 medical device registrations for quality control products and holds 90 national secondary standard material certificates[63] - The company launched multiple automated magnetic particle chemiluminescence immunoassay systems, with 126 supporting reagents already registered[100] - The company plans to increase R&D investment and achieve breakthroughs in patented technologies during the "14th Five-Year Plan" period[112] - The company aims to expand into the precision testing field and integrate advanced manufacturing with high-end services[112] Market and Industry Trends - The global in vitro diagnostics (IVD) market was approximately $127 billion in 2022 and is expected to reach $140 billion by 2027[34] - The IVD market is dominated by North America, Europe, and Japan, accounting for 44%, 20%, and 9% of the market share respectively[34] - Roche Diagnostics reported revenue of CHF 17.73 billion (approximately RMB 132.3 billion), a 2.5% year-over-year increase, driven by strong growth in immunodiagnostics[34] - Abbott Diagnostics reported revenue of $16.584 billion (approximately RMB 115.47 billion), a 6% year-over-year increase[34] - Danaher Diagnostics reported revenue of $10.849 billion (approximately RMB 75.54 billion), a 10.2% year-over-year increase[34] - Siemens Healthineers Diagnostics reported annual revenue of $6.399 billion, an 11.9% year-over-year increase[34] - The IVD market saw 47 M&A transactions in 2022, with three deals exceeding $1 billion, including Thermo Fisher's acquisition of The Binding Site Group for £2.25 billion ($2.68 billion)[35] - China's IVD industry is experiencing rapid growth, with significant advancements in molecular diagnostics and clinical mass spectrometry, driven by government policies and technological upgrades[38] - The Chinese government is actively promoting centralized procurement policies for IVD reagents, with a focus on cost control and market competition improvement[39] - The in vitro diagnostics industry in China is transitioning from the introduction phase to the growth phase, with domestic products reaching international leading levels in traditional testing fields[108] - Molecular diagnostics is the fastest-growing segment in the in vitro diagnostics industry, with applications expanding from infectious disease diagnosis to precision medicine and public health[109] - Mass spectrometry technology is emerging as the next blue ocean in the in vitro diagnostics field, with a potential market size of billions[110] Risk Factors and Management - The company's financial report includes detailed risk factors and management discussions, highlighting potential risks and mitigation strategies[5] - The company faces risks related to changes in national industry policies and regulatory requirements[114] - The company faces market risks due to intense competition in the in-vitro diagnostics (IVD) industry, with international companies dominating the high-end market in China[116] - The IVD industry in China is transitioning from a cultivation phase to a rapid growth phase, attracting more competitors and increasing market competition[116] - The company is focusing on maintaining its technological, market, brand, and customer trust advantages to cope with industry competition[116] - The company is at risk of technological obsolescence in the IVD industry, particularly in the chemiluminescence field, which is a mainstream clinical immunodiagnostic technology[116] - The company plans to increase investment in R&D for new products and technologies to keep up with industry trends and avoid falling behind in the market[116] - The company adheres to legal and compliant operations, continuously improving its management systems to adapt to new policies and reduce operational risks[115] - The company has a robust corporate governance structure, with clear responsibilities for the board of directors, supervisory board, and management to ensure the maximization of shareholder interests[118] - The company's controlling shareholder, Antu Industrial, maintains independence in personnel, finance, assets, and business operations, complying with regulatory requirements for listed companies[119] - The company held its 2021 annual general meeting on May 17, 2022, where 12 proposals were approved, including the 2021 financial report and the 2022 financial budget[121] - The company's board of directors, supervisory board, and senior management have clear roles and responsibilities, ensuring stable and healthy development[118] - The company has strengthened its internal control and risk management system in 2022, conducting special audits on key business modules and internal control execution[160] - The company upgraded and improved its financial management system (Cloud Cangqiong System) to enhance financial early warning capabilities and strengthen financial data analysis[162] Environmental and Social Responsibility - Environmental protection funds invested during the reporting period amounted to RMB 806.30 million[164] - Total wastewater discharge in 2022 was 133,068.3 tons, with COD daily average discharge concentration of 26.29mg/L and total COD discharge of 3.513 tons[166] - Medical waste in 2022 was fully handled by Zhengzhou Hanyang Tianchen Hazardous Waste Disposal Co., Ltd[166] - The average emission concentration of kitchen oil fume and non-methane total hydrocarbons were 0.35mg/m³ and 4.41mg/m³ respectively, with no concentration exceeding the standard[166] - The average emission concentration of hydrogen chloride, methanol, non-methane total hydrocarbons, and sulfuric acid mist in R&D waste gas were 2.38mg/m³, not detected, 0.28mg/m³, and 4.99mg/m³ respectively[167] - The maximum concentration of hydrogen chloride, methanol, sulfuric acid mist, and non-methane total hydrocarbons in the factory area were 0.196mg/m³, not detected, 0.071mg/m³, and 1.51mg/m³ respectively, all meeting the standard requirements[167] - The company has constructed a 500m³/d wastewater treatment station to ensure compliance with discharge standards[168] - Installed 3 sets of electrostatic oil fume separators and 1 set of online monitoring equipment for oil fume emissions[169] - Conducted semi-monthly testing of wastewater pollution factors (COD, ammonia nitrogen, pH) and regular third-party monitoring[172] - No environmental penalties were incurred during the reporting period from January 1, 2022 to December 31, 2022[173] - Implemented carbon reduction measures including intelligent temperature control for laboratory air supply units and optimization of central air conditioning and water pump operation mechanisms[176] - Total social responsibility investment reached 5.3021 million yuan, including 2.1012 million yuan in funds and 3.2009 million yuan in material donations[178] - Invested 1.5397 million yuan in poverty alleviation and rural revitalization projects, benefiting 330 individuals[179] - Established the "Antu Forward Scholarship" and "Antu Forward Veterans Comfort Fund" as part of educational and veteran support initiatives[180] - Donated 260,000 yuan to the "Emergency Assistance Charity Special Fund for Difficult Groups" in Henan Province[180] - Implemented environmental protection measures including installation of logistics access control systems and electricity monitoring devices for pollution control equipment[175] Corporate Governance and Leadership - Chairman Miao Yongjun holds 123,398,688 shares, a decrease of 145,474 shares compared to the beginning of the year[123] - Vice Chairman Zhang Yaxun holds 53,824,691 shares, with no change in shareholding[123] - General Manager Yang Zengli holds 29,645,403 shares, a decrease of 34,949 shares[123] - Deputy General Manager Wu Xuewei holds 29,645,403 shares, a decrease of 34,949 shares[123] - Executive Deputy General Manager Fu Guangyu holds 12,361,739 shares, a decrease of 14,573 shares[123] - CFO Feng Chaojie holds 9,216,111 shares, a decrease of 10,865 shares[123] - Board Secretary Fang Ruikuan holds 17,291,480 shares, a decrease of 20,385 shares[124] - Total shares held by executives decreased by 320,825 shares due to share lending through Antu Industrial[124] - Total pre-tax compensation for executives in the reporting period was 1,041.01 million yuan[124] - Fu Guangyu, born in 1969, holds a PhD and is a professor-level senior engineer. He has been with the company since 2003, holding various positions including R&D Manager, Deputy General Manager, and currently serves as Director and Executive Vice President[127] - Feng Chaojie, born in 1978, holds a master's degree and is a senior member of ACCA and a certified public accountant in China. She has been with the company since 2003, currently serving as Director, Deputy General Manager, and CFO[127] - Zhang He, born in 1964, holds a PhD and is an associate professor at Xi'an Jiaotong University. She has been an independent director of the company since 2022[127] - Li Zhijun, born in 1962, holds a bachelor's degree and is a senior engineer. He has been an independent director of the company since 2003[127] - Ye Zhongming, born in 1968, holds a master's degree and is a professor and certified public accountant. He has been an independent director of the company since 2018[129] - Han Mingming, born in 1970, holds an associate degree and is an accountant. He has been with the company since

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,036,466,641.85, representing a year-on-year increase of 0.52%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 242,069,910.75, with a year-on-year increase of 0.78%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 235,837,017.97, reflecting a year-on-year increase of 1.61%[4] - The basic and diluted earnings per share for Q1 2023 were both CNY 0.42, a decrease of 2.44% compared to the previous year[6] - Total revenue for Q1 2023 was approximately CNY 1,036.47 million, a slight increase from CNY 1,031.15 million in Q1 2022, representing a growth of 0.33%[16] - Net profit for Q1 2023 was CNY 247.17 million, compared to CNY 246.97 million in Q1 2022, showing a marginal increase of 0.08%[17] - The total comprehensive income for Q1 2023 was CNY 247.05 million, slightly higher than CNY 246.93 million in Q1 2022, indicating a growth of 0.05%[17] Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 203,712,193.35, showing a significant increase of 11.95% year-on-year[4] - Cash flow from operating activities increased to CNY 1,194.25 million in Q1 2023, compared to CNY 1,155.24 million in Q1 2022, reflecting a growth of 3.38%[19] - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency and revenue generation capabilities[20] - The overall cash position decreased by ¥408,207,092.06 compared to an increase of ¥144,261,270.20 in the same quarter last year[20] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 10,512,372,555.85, an increase of 0.38% from the end of the previous year[6] - The equity attributable to shareholders at the end of Q1 2023 was CNY 8,024,541,579.52, reflecting a year-on-year increase of 3.11%[6] - The total liabilities of the company were CNY 2.35 billion, down from CNY 2.56 billion, reflecting a decrease of 8.06%[15] - The company's total equity increased to CNY 8.16 billion from CNY 7.91 billion, representing a growth of 3.16%[15] Investments and Expenses - Research and development expenses rose to CNY 152.42 million in Q1 2023, up from CNY 120.79 million in Q1 2022, an increase of 26.19%[16] - Sales expenses decreased to CNY 170.45 million in Q1 2023 from CNY 189.10 million in Q1 2022, a decline of 9.83%[16] - The company reported an increase in investment income to CNY 37.06 million in Q1 2023, compared to CNY 27.80 million in Q1 2022, a growth of 33.38%[16] Cash and Cash Equivalents - The company's cash and cash equivalents were reported at CNY 729.41 million, down from CNY 1.14 billion year-over-year, indicating a decline of 35.87%[13][14] - The cash and cash equivalents at the end of Q1 2023 were ¥728,394,172.47, down from ¥911,656,426.48 at the end of Q1 2022[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was not specified, but the largest shareholder held 55.24% of the shares[9] Non-Recurring Items - The company reported non-recurring gains of CNY 6,232,892.78 for the period, after accounting for tax and minority interests[8] Other Information - The company has not disclosed any new product launches or technological advancements in this report[12] - The company has not adopted new accounting standards or interpretations for the year 2023[21]

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,211,231,405.06, representing a year-on-year increase of 19.02%[4] - The net profit attributable to shareholders for the same period was ¥365,365,458.84, reflecting a growth of 20.23% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥354,873,633.48, with a year-on-year increase of 15.47%[4] - The basic earnings per share for Q3 2022 was ¥0.63, up 21.15% from the same period last year[5] - Operating profit for Q3 2022 was ¥1,024,790,143.90, up 26.5% from ¥809,742,616.52 in Q3 2021[17] - Net profit attributable to shareholders of the parent company for Q3 2022 was ¥898,886,168.12, an increase of 25.4% compared to ¥716,573,599.07 in Q3 2021[17] - The total comprehensive income for Q3 2022 was ¥916,703,080.59, compared to ¥724,411,245.50 in Q3 2021, reflecting a growth of 26.6%[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥10,229,578,454.31, an increase of 10.80% compared to the end of the previous year[5] - The total liabilities stood at CNY 6.15 billion, with short-term borrowings slightly increasing to CNY 100.08 million from CNY 100.06 million[13] - The total liabilities increased to ¥2,571,907,750.58 in Q3 2022 from ¥1,829,490,502.60 in Q3 2021, reflecting a growth of 40.5%[15] - The company's total equity reached ¥7,657,670,703.73 in Q3 2022, compared to ¥7,403,203,912.94 in Q3 2021, marking an increase of 3.4%[15] - The company's total liabilities and equity reached ¥10,229,578,454.31 in Q3 2022, up from ¥9,232,694,415.54 in Q3 2021, indicating a growth of 10.8%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,008,547,134.85, reflecting an increase of 8.01%[5] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 1,008,547,134.85, an increase of 8.0% compared to CNY 933,770,922.23 in the same period of 2021[20] - Total cash inflow from operating activities reached CNY 3,617,051,516.19, up from CNY 3,111,829,528.21, reflecting a growth of 16.2% year-over-year[20] - Cash outflow for purchasing goods and services was CNY 1,177,377,937.04, compared to CNY 1,052,019,729.95 in the previous year, indicating a rise of 11.9%[20] - The net cash flow from investment activities was -CNY 855,683,891.09, worsening from -CNY 292,539,347.14 in the same period last year[21] - The net cash flow from financing activities was -CNY 75,024,124.23, an improvement from -CNY 429,197,726.14 in the previous year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,333[8] - The company’s major shareholder, Zhengzhou Antu Industrial Group, holds 323,821,073 shares, representing a significant portion of the total shares outstanding[10] - The company has a share repurchase account holding 5,260,910 shares, accounting for approximately 0.90% of the total share capital[10] - The report indicates that there are no known relationships or concerted actions among the top ten shareholders, ensuring independent ownership structures[10] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥396,959,203.55, up 17.4% from ¥337,848,595.48 in the same period of 2021[16] Other Financial Metrics - The company had a weighted average return on equity of 4.97% for the quarter, an increase of 0.54 percentage points year-on-year[5] - Non-recurring gains for Q3 2022 totaled ¥10,491,825.36, with a year-to-date total of ¥38,789,436.10[7] - The company reported a net impairment loss of ¥15,916,240.94 in Q3 2022, compared to a loss of ¥11,890,686.31 in Q3 2021[17] - The company's cash and cash equivalents reached CNY 849.35 million, up from CNY 769.40 million year-over-year, indicating a growth of approximately 10.5%[12] - Accounts receivable increased to CNY 1.13 billion from CNY 989.06 million, representing a rise of about 14.5%[12] - Inventory levels rose to CNY 787.30 million, compared to CNY 589.34 million in the previous year, marking an increase of approximately 33.6%[13] - The total current assets were reported at CNY 6.15 billion, up from CNY 5.56 billion, which is an increase of around 10.7%[13] - The company’s long-term equity investments increased significantly to CNY 8.60 million from CNY 1.72 million, reflecting a growth of approximately 400%[13]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a 15% increase compared to the same period last year[13]. - The net profit attributable to shareholders was 100 million RMB, showing a growth of 20% year-on-year[13]. - The company's operating revenue for the first half of 2022 was approximately CNY 2.07 billion, representing a year-on-year increase of 23.41% compared to CNY 1.68 billion in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was approximately CNY 533.52 million, reflecting a year-on-year growth of 29.28% from CNY 412.68 million[18]. - The basic earnings per share for the first half of 2022 was CNY 0.91, up 30.00% from CNY 0.70 in the same period last year[19]. - The total profit for the first half of 2022 was CNY 612,156,273.47, a significant increase from CNY 457,229,951.10 in the previous year, marking a growth of 33.9%[122]. - The total comprehensive income for the first half of 2022 was CNY 548,715,232.55, compared to CNY 418,983,052.13 in the same period last year, representing a growth of 30.9%[123]. - The company's operating profit for the first half of 2022 was CNY 611,763,697.95, an increase of 33.5% from CNY 457,886,941.74 in the same period last year[122]. User Growth and Market Position - User data indicates an increase in active users by 30%, reaching a total of 1 million users by the end of June 2022[13]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2022, driven by market expansion and new product launches[13]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product offerings[13]. - The company operates in the in vitro diagnostic (IVD) product manufacturing industry, which is part of the medical device sector[22]. - The global IVD market was approximately USD 117 billion in 2021, with significant growth driven by advancements in genomic testing technologies[24]. - Major players in the global IVD market include Roche, Abbott, and Danaher, with Roche's revenue for the first half of 2022 reported at approximately CNY 70 billion[24]. Research and Development - Research and development expenses increased by 25%, reflecting the company's commitment to innovation and new technology development[13]. - The company has a total of 1,635 R&D personnel, accounting for 30.69% of the total workforce, with 89.91% holding a bachelor's degree or higher[44]. - R&D investments from 2019 to 2021 were CNY 311.91 million, CNY 346.37 million, and CNY 485.95 million, representing 11.64%, 11.63%, and 12.90% of revenue respectively[44]. - The company has obtained 1,033 patents, including 50 international patents, and has registered 617 products, with 435 receiving EU CE certification[44]. - The company emphasizes the R&D of core materials, achieving self-sufficiency in key raw materials such as antigens and antibodies[45]. Environmental and Social Responsibility - The company reported a total wastewater discharge of 73,679.95 tons from January 1 to June 30, 2022, with an average COD discharge concentration of 30.4 mg/L and a total COD discharge of 2.24 tons[84]. - The company has established a hazardous waste storage area to properly manage and dispose of various types of hazardous waste[84]. - The company has implemented emergency management measures in response to the COVID-19 pandemic, which has impacted the industry and reduced the consumption of reagents due to fewer routine hospital visits[79]. - A total of 1300 students have benefited from the "Antu Forward Scholarship" established in 19 universities, with an additional donation of 30,000 yuan in 2022[95]. - The company has provided cash assistance to over 500 veterans in Nanyang, Henan, as part of its social responsibility initiatives[96]. Financial Position and Investments - The company has maintained a strong cash position, with cash and cash equivalents totaling 200 million RMB as of June 30, 2022[13]. - The company's total assets at the end of the reporting period were approximately CNY 9.64 billion, a year-on-year increase of 4.41% from CNY 9.23 billion[18]. - The company's total liabilities amounted to RMB 2,312,368,075.94, compared to RMB 1,829,490,502.60 at the beginning of the period, reflecting an increase of approximately 26.4%[116]. - The company reported a significant decrease in investment cash flow, with a net outflow of CNY 592.18 million, compared to a net inflow of CNY 99.79 million in the previous year, marking a change of -693.43%[68]. - The company has increased its long-term equity investment by 446.66% to CNY 9.43 million, up from CNY 1.72 million year-on-year[70]. Corporate Governance and Compliance - The board of directors has approved a plan to reinvest profits into the business for further growth and expansion[3]. - The company has identified key risks in its operational processes and has outlined strategies to mitigate these risks in the report[5]. - The company emphasizes compliance with national policies and continuously improves its management levels to adapt to changes in regulatory requirements[78]. - The company has established a dedicated "Safety and Environmental Protection Department" responsible for environmental protection work and has obtained ISO14001 certification[92]. - The company has not proposed any profit distribution or capital reserve increase plans for the current period[82].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,031,147,048.85, representing a year-on-year increase of 26.21%[4] - The net profit attributable to shareholders was CNY 240,200,411.27, reflecting a growth of 40.07% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 232,096,786.92, an increase of 37.36% year-on-year[4] - The basic and diluted earnings per share were both CNY 0.41, marking a rise of 41.38% from the previous year[5] - Total operating revenue for Q1 2022 reached ¥1,031,147,048.85, a 26.1% increase from ¥817,001,562.13 in Q1 2021[18] - Net profit for Q1 2022 was ¥246,970,997.71, representing a 41.0% increase compared to ¥175,062,601.81 in Q1 2021[19] - Total profit for Q1 2022 was ¥284,445,290.79, compared to ¥192,568,587.71 in Q1 2021, marking a 47.8% increase[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 9,628,036,184.62, up 4.28% from the end of the previous year[5] - The company's total assets amounted to approximately ¥9.63 billion, an increase from ¥9.23 billion as of December 31, 2021, representing a growth of about 4.4%[16] - The total liabilities of the company were approximately ¥2.05 billion, an increase from ¥1.83 billion, which is a rise of about 12.1%[16] - The company's equity attributable to shareholders was approximately ¥7.44 billion, up from ¥7.28 billion, showing an increase of about 2.3%[16] Cash Flow - The net cash flow from operating activities was CNY 181,963,679.96, which decreased by 29.85% year-on-year[4] - Cash flow from operating activities for Q1 2022 was ¥181,963,679.96, down 29.8% from ¥259,377,417.68 in Q1 2021[20] - Total cash and cash equivalents at the end of the period reached $911.7 million, up from $370.8 million in the previous period, indicating a significant increase of 145%[21] - The net increase in cash and cash equivalents for the period was $144.3 million, compared to an increase of $43.3 million in the previous period, representing a growth of over 233%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,030[9] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., held 55.25% of the shares[9] Expenses - Research and development expenses for Q1 2022 totaled ¥120,785,632.35, an increase of 16.4% from ¥103,758,719.19 in Q1 2021[18] - Sales expenses for Q1 2022 were ¥189,098,011.68, up 22.7% from ¥154,143,382.03 in Q1 2021[18] Other Financial Metrics - The weighted average return on equity increased by 0.64 percentage points to 3.25%[5] - The company's current assets reached approximately ¥5.84 billion, up from ¥5.56 billion in the previous year, indicating an increase of around 5.1%[14] - Cash and cash equivalents stood at approximately ¥913.66 million, compared to ¥769.40 million in the same period last year, reflecting a growth of about 18.7%[14] - The accounts receivable amounted to approximately ¥989.30 million, slightly up from ¥989.06 million, indicating a marginal increase of about 0.02%[14] - The inventory value increased to approximately ¥681.07 million from ¥589.34 million, representing a growth of about 15.6%[14] - The company reported a short-term loan of ¥100 million, consistent with the previous year's figure of ¥100.06 million[16] - The total non-current assets were approximately ¥3.79 billion, an increase from ¥3.67 billion, reflecting a growth of about 3.0%[15] - The company's other receivables increased to approximately ¥30.92 million from ¥28.80 million, indicating a growth of about 7.4%[14] Comprehensive Income - The company reported a decrease in comprehensive income for Q1 2022, totaling ¥246,929,536.64 compared to ¥175,181,369.97 in Q1 2021[19] Investment Activities - Cash flow from investment activities showed a net outflow of $238.7 million, compared to a net inflow of $23.4 million in the previous period[21] - The company reported a total investment cash outflow of $520 million, down from $609.2 million in the previous period, indicating a reduction of approximately 14.6%[21] Financing Activities - Cash inflow from financing activities totaled $390 million, a substantial increase compared to $2.1 million in the previous period[21] - Cash outflow for financing activities was $186.9 million, down from $241.8 million in the previous period, reflecting a decrease of approximately 22.7%[21] Accounting Standards - The company did not apply the new accounting standards for the current year, as indicated in the report[21] Report Release - The report was released by the board of directors on April 25, 2022, under the supervision of key financial personnel[21]

Financial Performance - In 2021, the company achieved a revenue of 3.766 billion RMB, representing a year-on-year growth of 26.45%[2] - The net profit attributable to shareholders was 974 million RMB, with a year-on-year increase of 30.20%[2] - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year growth of 15%[10] - The company achieved operating revenue of CNY 3.77 billion in 2021, representing a year-on-year growth of 26.45%[25] - Net profit attributable to shareholders reached CNY 973.66 million, an increase of 30.20% compared to the previous year[25] - The company has set a revenue guidance of RMB 1.5 billion for the upcoming fiscal year, indicating a projected growth of 25%[10] - The company reported a quarterly revenue of CNY 1.07 billion in Q4 2021, showing a strong performance in the last quarter[20] - The company achieved a revenue of CNY 3,765.92 million in 2021, an increase of CNY 787.79 million, representing a year-on-year growth of 26.45%[68] - The net profit attributable to shareholders was CNY 973.66 million, up CNY 225.87 million, with a year-on-year growth of 30.20%[68] Research and Development - Research and development investment reached 12.90% of revenue in 2021, continuing a trend of over 11% in previous years[2] - The company plans to invest approximately 4 billion RMB in research and development during the 14th Five-Year Plan period, significantly expanding its product line[4] - The company has invested RMB 200 million in R&D for new technologies, focusing on enhancing diagnostic accuracy[10] - R&D investment from 2019 to 2021 was 311.91 million, 346.37 million, and 485.95 million CNY, representing 11.64%, 11.63%, and 12.90% of revenue respectively[51] - The company has established a high-quality R&D team with 1,607 personnel, accounting for 31.94% of total employees, and 89.73% of R&D staff hold a bachelor's degree or higher[51] - The company launched several new products, including the AutoLumo A1800 and A6000 series immunoassay analyzers, and the AutoStreak S1800 microbial sample processing system[3] - The company launched an automatic nucleic acid purification and real-time fluorescence PCR analysis system in July 2021, enhancing efficiency in medical laboratories[26] - The company has developed multiple technical platforms for various diagnostic reagents, ensuring product quality and timely technical service[54] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[10] - The company is focusing on automation and intelligent manufacturing, with the launch of the Autolas X-1 series products aimed at enhancing its position in laboratory automation[4] - The company is actively responding to industry changes, including centralized procurement and healthcare payment reforms, to maintain steady growth[2] - The company is expanding its product line through strategic collaborations, including partnerships with Hiken Medical and Sekisui Medical in the coagulation testing field[27] - The company aims to enhance service quality with a technical service team of over 1,000 members, focusing on clinical laboratory quality control[27] - The company is expanding into non-infectious disease areas, achieving a balanced development in both infectious and non-infectious disease applications[55] - The company plans to increase its production capacity by 50% to meet rising demand for its products[10] Financial Management and Governance - A cash dividend of 7.2 RMB per 10 shares (including tax) is proposed, totaling approximately 419.84 million RMB, which accounts for 43.12% of the net profit attributable to shareholders[5] - The company has established a comprehensive salary and performance evaluation system, combining fixed and variable compensation based on key performance indicators[151] - The company has a cash dividend policy in place, ensuring the distribution of profits to shareholders[153] - The company has established a profit distribution policy prioritizing cash dividends, with a minimum cash distribution of 20% of the distributable profit for the year[154] - The internal control system has been established based on the Ministry of Finance's guidelines, ensuring effective financial reporting controls as of December 31, 2021[163] - The company has implemented a comprehensive budget system to enhance financial management and risk control across subsidiaries[162] - The company has committed to transparency in its financial reporting and governance practices, as evidenced by the detailed reports presented in board meetings[141] Environmental and Social Responsibility - The company has established a dedicated environmental protection department and has obtained ISO 14001 certification for its environmental management system[173] - The company has implemented energy-saving measures, resulting in a reduction of approximately 133,600 sheets of paper through online office practices in 2021[175] - The company established the "Antu Qianjin Scholarship" and other initiatives, donating a total of RMB 555,000 to support 207 students in 2021[177] - The company provided assistance to 130 veterans in 2021, with a total support amount of RMB 650,000[178] - The company has commitments related to the issuance of convertible bonds, ensuring measures to compensate for the dilution of immediate returns[182] - The company has pledged to support veterans from various wars, reflecting its commitment to social welfare[178] Challenges and Risks - The impact of the COVID-19 pandemic has led to a decrease in patient visits and testing product usage, posing challenges to the company's growth[2] - The company faces risks related to changes in industry policies and regulations that could impact its operations and market access[111] - The company continues to enhance its operational management and control systems to adapt to new policies and reduce operational risks due to policy changes[112] - The COVID-19 pandemic has impacted the company's performance, leading to increased product costs and reduced consumption of diagnostic reagents due to fewer hospital visits[113] Shareholder and Management Structure - The company’s major shareholder, Antu Industrial, maintains independence in operations, finance, and business, adhering to regulatory requirements[115] - The company held its annual shareholder meeting on May 13, 2021, where 12 proposals were approved without any rejections[116] - The company’s first extraordinary shareholder meeting in 2021 took place on October 28, approving 4 proposals, including the election of non-independent directors[118] - The total number of shares held by the chairman, Miao Yongjun, increased from 94,834,106 to 123,544,162, reflecting a change of 28,710,056 shares[121] - The total number of shares held by the total number of shares held by all executives increased from 250,547,187 to 326,284,351, reflecting an overall increase of 75,737,163 shares[122]

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,017,639,627.62, representing a year-on-year increase of 20.92%[4] - The net profit attributable to shareholders for the same period was ¥303,895,597.88, reflecting a growth of 26.45% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥307,327,926.66, which is an increase of 38.18% year-on-year[4] - The basic earnings per share for Q3 2021 was ¥0.52, up by 20.93% year-on-year[5] - The company reported a year-to-date net profit growth of 39.33%, driven by increased revenue and reduced non-recurring losses[9] - The diluted earnings per share for the year-to-date period was ¥1.22, representing a year-on-year increase of 32.61%[5] - Net profit for Q3 2021 was ¥724,329,571.32, representing a 39.3% increase compared to ¥519,954,326.06 in Q3 2020[19] - Earnings per share for Q3 2021 was ¥1.22, compared to ¥0.92 in Q3 2020, reflecting a 32.6% increase[20] Cash Flow - The cash flow from operating activities for the year-to-date period reached ¥933,770,922.23, showing a significant increase of 191.08% compared to the same period last year[4] - The company experienced a significant increase in cash flow due to higher sales collections during the reporting period[9] - Operating cash inflow for the first nine months reached CNY 3,111,829,528.21, a significant increase from CNY 2,127,606,703.00 in the same period last year, reflecting a growth of approximately 46.3%[21] - Net cash flow from operating activities for the first nine months was CNY 933,770,922.23, compared to CNY 320,793,865.61 in the previous year, indicating a growth of about 191.5%[21] - Cash inflow from the sale of goods and services of CNY 2,977,288,864.34 for the first nine months, compared to CNY 1,971,196,231.24 in the same period last year, representing a growth of approximately 50.9%[21] - Cash outflow for operating activities totaled CNY 2,178,058,605.98, an increase from CNY 1,806,812,837.39 in the previous year, reflecting a rise of about 20.5%[21] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥8,831,122,324.15, an increase of 8.53% from the end of the previous year[5] - The total liabilities increased to ¥1,684,041,384.08 in Q3 2021, up from ¥1,551,830,613.40 in Q3 2020, marking an 8.5% rise[17] - The total equity attributable to shareholders reached ¥7,019,028,364.53, an increase of 8.4% from ¥6,477,364,992.31 in the previous year[17] - The company's total assets reached ¥8,831,122,324.15, up from ¥8,137,141,424.06 at the end of 2020[15] - Total current assets increased to ¥5,297,146,962.23 from ¥5,094,706,551.38 year-over-year[15] - Accounts receivable stood at ¥959,548,747.10, slightly up from ¥956,321,567.00 in the previous year[15] - Inventory increased to ¥588,528,054.20 from ¥475,522,514.41 year-over-year[15] - The company reported a significant increase in long-term construction projects, with amounts rising to ¥1,010,494,938.09 from ¥641,796,635.03[15] Shareholder Information - Total number of common shareholders at the end of the reporting period was 43,327[11] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 323,524,173 shares, accounting for 55.18% of total shares[11] Research and Development - Research and development expenses for the first three quarters of 2021 were ¥337,848,595.48, up from ¥236,095,886.07 in the same period of 2020, indicating a 43.1% increase[18] - The company has no reported new product launches or technological developments in this quarter[13] Mergers and Acquisitions - There are no significant mergers or acquisitions reported during this period[13] Investment Income - The company reported investment income of ¥80,526,152.21 in Q3 2021, compared to ¥38,324,337.79 in Q3 2020, which is a 109.5% increase[19] Tax Liabilities - The deferred income tax liabilities increased to ¥305,336,611.15 in Q3 2021 from ¥236,607,303.92 in Q3 2020, a rise of 29.0%[17]